Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  1996-11-12

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/PNAS.93.23.13114PMID 8917553PMCID PMC24055
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Differential transport requirements of HLA and H-2 class I glycoproteins

  2004cited by this paper
• A synthetic peptide derived from the tumor-associated protein mdm2 can stimulate autoreactive, high avidity cytotoxic T lymphocytes that recognize naturally processed protein.

  1996cited by this paper
• Human tumor antigens recognized by T lymphocytes

  1996cited by this paper
• BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes.

  1995cited by this paper
• Targeting p53 as a general tumor antigen.

  1995cited by this paper
• A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma

  1995cited by this paper
• Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines.

  1994cited by this paper
• Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.

  1994cited by this paper
• Limitations of predictive motifs revealed by cytotoxic T lymphocyte epitope mapping of the human papilloma virus E7 protein.

  1994cited by this paper
• A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

  1994cited by this paper
• Cyclin D1 protein expression and function in human breast cancer

  1994cited by this paper
• Melanocyte lineage-specific antigen gp100 is recognized by melanoma- derived tumor-infiltrating lymphocytes

  1994cited by this paper
• The p53-mdm-2 autoregulatory feedback loop.

  1993cited by this paper
• The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

  1993cited by this paper
• The human MDM-2 oncogene is overexpressed in leukemias.

  1993cited by this paper
• Major histocompatibility complex (MHC)-encoded HAM2 is necessary for antigenic peptide loading onto class I MHC molecules.

  1992cited by this paper
• A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

  1991cited by this paper
• The dendritic cell system and its role in immunogenicity.

  1991cited by this paper
• Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line.

  1991cited by this paper
• Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies.

  1991cited by this paper
• Allogeneic bone marrow transplantation: state of the art and future directions.

  1989cited by this paper
• Primary stimulation by dendritic cells induces antiviral proliferative and cytotoxic T cell responses in vitro

  1989cited by this paper
• Graft-versus-host disease following transplantation of 'one log' versus 'two log' T-lymphocyte-depleted bone marrow from HLA-identical donors.

  1986cited by this paper
• Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism

  1985cited by this paper
• Self tolerance is H–2-restricted

  1984cited by this paper
• Evidence from in vitro studies that tolerance to self antigens is MHC-restricted

  1984cited by this paper
• Is self tolerance H–2 restricted?

  1980cited by this paper
• Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines.

  1976cited by this paper

• Advances in melanoma immunotherapy: harnessing vaccination as a potential novel immunotherapeutic strategy.

  2026cites this paper
• TCR-based therapy directed against kallikrein-related peptidase 4 is safe and effective against prostate cancer.

  2025cites this paper
• A library of cancer testis specific T cell receptors for T cell receptor gene therapy

  2022cites this paper
• Non-Mutated Nucleophosmin 1 Is Recognized by the CD8+ T Lymphocytes of an AML Patient after the Transplantation of Hematopoietic Stem Cells from an HLA-Haploidentical Donor

  2022cites this paper
• T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes

  2021cites this paper
• Generation of Epstein-Barr Virus Antigen-Specific T Cell Receptors Recognizing Immunodominant Epitopes of LMP1, LMP2A, and EBNA3C for Immunotherapy

  2021cites this paper
• Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy

  2021cites this paper
• Empirical and Rational Design of T Cell Receptor-Based Immunotherapies

  2021cites this paper
• Immunopathology and Immunotherapy of Myeloid Leukemia

  2020cites this paper
• Tools to define the melanoma‐associated immunopeptidome

  2017cites this paper
• Turn to TCRs when CARs fail

  2017cites this paper
• No hiding place for BOB inside myeloma.

  2017cites this paper
• How an alloreactive T-cell receptor achieves peptide and MHC specificity

  2017cites this paper
• T‐cell receptor gene therapy — ready to go viral?

  2015cites this paper
• Identities of P2 and P3 Residues of H-2Kb-Bound Peptides Determine Mouse Ly49C Recognition

  2015cites this paper
• Dependency of Ly49 Recognition on Anchor Residues of Peptide Bound to MHC-I

  2015cites this paper
• Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice

  2015cites this paper
• T-cell receptor gene therapy e ready to go viral? 5

  2015cites this paper
• Enhancing the efficacy of TCR gene therapy

  2014cites this paper
• Cellular immunotherapy strategies for Ewing sarcoma.

  2014cites this paper
• Common Ewing sarcoma-associated antigens fail to induce natural T cell responses in both patients and healthy individuals

  2014cites this paper
• Engineered To Express the Same T Cell Self-Antigen Is Reversed by CD4 T Cells CD8 T Cell Tolerance to a Tumor-Associated

  2014influential citation
• P64. T cell re-direction against Glypican-3 for immunotherapy of hepatocellular carcinoma

  2014cites this paper
• CD8 T Cell Tolerance to a Tumor-Associated Self-Antigen Is Reversed by CD4 T Cells Engineered To Express the Same T Cell Receptor

  2014influential citation
• Adoptive T-Cell Immunotherapy: Perfecting Self-Defenses

  2014cites this paper
• Tolerance to a Tumor-Associated Self-Antigen Is Reversed by CD 4 T Cells Engineered To Express the Same T Cell Receptor

  2014influential citation
• lymphocytes specific for WT1 Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T

  2013cites this paper
• CD8 co-receptor modifications to enhance T cell immunotherapy

  2013cites this paper
• 1 can function as targets for leukemia-reactive CTL presented epitopes of the Wilms tumor antigen - Two distinct HLA-A0201

  2013cites this paper
• High-throughput identification of antigen-specific TCRs by TCR gene capture

  2013cites this paper
• relapsed leukemia after HLA-mismatched stem cell transplantation T cells restricted by nonself HLA molecules: a potential strategy to treat specific cytotoxic - Generation of minor histocompatibility antigen HA-1

  2013cites this paper
• Can immunotherapy specifically target acute myeloid leukemic stem cells?

  2013cites this paper
• Cancer regression and neurological toxicity cases after anti-MAGE-A3 TCR gene therapy.

  2013cites this paper
• Blockade of TGF-β Signaling Greatly Enhances the Efficacy of TCR Gene Therapy of Cancer

  2013cites this paper
• Challenges in T cell receptor gene therapy

  2012cites this paper
• Improving TCR Gene Therapy for Treatment of Haematological Malignancies

  2012cites this paper
• How (specific) would you like your T-cells today? Generating T-cell therapeutic function through TCR-gene transfer

  2012cites this paper
• Isolation of human MHC class II‐restricted T cell receptors from the autologous T‐cell repertoire with potent anti‐leukaemic reactivity

  2012cites this paper
• Genetically modulating T-cell function to target cancer.

  2012cites this paper
• Functional characterization of allorestricted T cell receptors (TCRs) with specificity for HER2/neu and FMNL1 in vitro and in vivo for potential clinical application

  2011influential citation
• Adoptive Immunotherapy after Allogeneic Hematopoietic Progenitor Cell Transplantation: New Perspectives for Transfusion Medicine

  2011cites this paper
• T-cell receptor gene therapy: critical parameters for clinical success.

  2011cites this paper
• Regulatory T-cell adoptive immunotherapy: potential for treatment of autoimmunity

  2011cites this paper
• Immunotherapy for myeloproliferative neoplasms (MPN).

  2011cites this paper
• T cell gene-engineering to enhance GVT and suppress GVHD.

  2011cites this paper
• Structural and energetic evidence for highly peptide-specific tumor antigen targeting via allo-MHC restriction

  2011cites this paper
• Generation of autologous and allorestricted cytotoxic T cell clones directed against Ewing Tumor antigens

  2010cites this paper
• Enhanced T cell receptor gene therapy for cancer

  2010cites this paper
• The Role of CD8 T Cells in the Control of Infectious Disease and Malignancies

  2010cites this paper
• A Single TCRα-Chain with Dominant Peptide Recognition in the Allorestricted HER2/neu-Specific T Cell Repertoire

  2009cites this paper
• In vivo anti-melanoma efficacy of allo-restricted CTLs specific for melanoma expanded by artificial antigen-presenting cells

  2009cites this paper
• TCR transgenes and transgene cassettes for TCR gene therapy: status in 2008

  2009cites this paper
• Raising allo-restricted cytotoxic T lymphocytes by co-culture of murine splenocytes with autologous macrophage bearing the peptide/allo-major histococompatibility complex.

  2009cites this paper
• Preclinical development of T cell receptor gene therapy.

  2009cites this paper
• A Single TCRa-Chain with Dominant Peptide Recognition in the Allorestricted HER2/neu-Specific T Cell Repertoire

  2009cites this paper
• Retroviral transfer of a dominant TCR prevents surface expression of a large proportion of the endogenous TCR repertoire in human T cells

  2008cites this paper
• T-cell receptor gene transfer for treatment of leukemia.

  2008cites this paper
• MHC restriction and allogeneic immune responses

  2008cites this paper
• Manipulation of MHC-I/TCR Interaction for Immune Therapy

  2008cites this paper
• Generation and characterization of transgenic mice expressing a T‐cell receptor specific for the tumour‐associated antigen MDM2

  2008cites this paper
• Generation of allo-restricted cytotoxic T lymphocytes against malignant glioma by artificial antigen-presenting cells.

  2007cites this paper
• Promiscuity of the AlloHLA-A2 restricted T cell repertoire hampers the generation of minor Histocompatibility antigen-specific cytotoxic T cells across HLA barriers.

  2007cites this paper
• Dendritic Cell Immunization Induces Nonprotective WT1-specific CTL Responses in Mouse

  2007cites this paper
• CD8alpha/alpha homodimers fail to function as co-receptor for a CD8-dependent TCR.

  2007cites this paper
• Redirecting T lymphocyte specificity by T cell receptor gene transfer--a new era for immunotherapy.

  2007cites this paper
• CD8α/α homodimers fail to function as co‐receptor for a CD8‐dependent TCR

  2007cites this paper
• Enhancing immune responses for cancer therapy.

  2007cites this paper
• A Study of T Cell Tolerance to the Tumor-Associated Antigen MDM2: Cytokines Can Restore Antigen Responsiveness, but Not High Avidity T Cell Function

  2007influential citation
• Intrathymic selection: new insight into tumor immunology.

  2007cites this paper
• Identifikation von Antigenen eines großzelligen Medulloblastoms mittels der autologen serologischen Analyse einer Tumor cDNA-Expressionsbibliothek (SEREX)

  2006cites this paper
• Single MHC-Peptide Complex Allo-MHC-Restricted T Cells Specific for a Ex Vivo Characterization of

  2006influential citation
• Ex Vivo Characterization of Allo-MHC-Restricted T Cells Specific for a Single MHC-Peptide Complex1

  2006influential citation
• Generation of tumor-specific T-cell therapies.

  2006cites this paper
• Towards immunogene therapy of hematological malignancies.

  2006cites this paper
• Exploiting beneficial alloreactive T cells

  2006cites this paper
• Antigen-specific cellular immunotherapy of leukemia

  2005cites this paper
• Exploiting T cell receptor genes for cancer immunotherapy

  2005cites this paper
• Direct recognition by alphabeta cytolytic T cells of Hfe, a MHC class Ib molecule without antigen-presenting function.

  2005cites this paper
• MHC Restriction and Allogeneic Immune Response

  2005cites this paper
• New Books

  2005influential citation
• Immunotherapy: target the stroma to hit the tumor.

  2005cites this paper
• Broadly expressed tumour?associated proteins as targets for cytotoxic T lymphocyte-based cancer immunotherapy

  2005influential citation
• Allogeneic T lymphocytes as a source of peptide-dependent T cells specific for myeloma cells.

  2005cites this paper
• [Gene therapy for leukemia].

  2005cites this paper
• Secretomers as a new tool for the monitoring of CTL responses

  2005cites this paper
• Induction of Unresponsiveness Limits Tumor Protection by Adoptively Transferred MDM2-Specific Cytotoxic T Lymphocytes

  2004cites this paper
• Treatment of advanced Ewing tumors by combined radiochemotherapy and engineered cellular transplants

  2004cites this paper
• Cutting Edge: Identification of Hepatitis C Virus-Specific CD8+ T Cells Restricted by Donor HLA Alleles following Liver Transplantation1

  2004cites this paper
• WT1-targeted immunotherapy of leukaemia.

  2004cites this paper
• Incomplete tolerance to the tumour-associated antigen MDM2.

  2004influential citation
• In vitro generation of cytolytic T cells against human melanoma cells overexpressing HDM2.

  2004cites this paper
• Use of the allogeneic TCR repertoire to enhance anti-tumor immunity.

  2004cites this paper
• HLA Alleles following Liver T Cells Restricted by + Virus-Specific CD 8 Cutting Edge : Identification of Hepatitis C Nishimura

  2004cites this paper
• Exploiting alloreactivity for tumour immunotherapy

  2004cites this paper
• The MBP-reactive repertoire is shaped by recognition of minor histocompatibility antigens.

  2004cites this paper
• TCR gene therapy of leukemia

  2003cites this paper
• WT1 as target for tumor immunotherapy

  2003cites this paper
• Tissue-restricted T cell alloresponses across HLA barriers: selection and identification of leukemia-restricted CTL in HLA-mismatched stimulator–responder pairs

  2003cites this paper
• Prospects for immunotherapy of malignant disease

  2003cites this paper
• Targeting Alloreactive Donor T-Cells to Hematopoietic System-Restricted Minor Histocompatibility Antigens to Dissect Graft-versus-Leukemia Effects from Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation

  2003cites this paper